# Clinical and pathophysiological links between hypoglycemia and cardiovascular risk in type 2 diabetes mellitus

**Authors:** Lamija Ferhatbegović, Minela Bećirović, Emir Bećirović, Sumeja Sarajlić, Aida Ribić, Asja Šarić, Amir Bećirović, Belma Pojskić

PMC · DOI: 10.3389/fcdhc.2026.1765597 · Frontiers in Clinical Diabetes and Healthcare · 2026-02-05

## TL;DR

Severe low blood sugar in type 2 diabetes is linked to higher heart disease risk due to stress on the body and blood vessels.

## Contribution

This paper reviews clinical and biological connections between severe hypoglycemia and cardiovascular risk in diabetes.

## Key findings

- Severe hypoglycemia is associated with increased coronary heart disease and cardiovascular events in diabetes patients.
- Hypoglycemia triggers inflammation, blood clotting, and heart stress, worsening cardiovascular outcomes.
- Recurrent hypoglycemia may lead to microvascular dysfunction and adverse heart remodeling in diabetes.

## Abstract

Severe hypoglycemia increases the risk of cardiovascular disease (CVD) in people with diabetes. Large cohort studies and scientific statements show that severe hypoglycemia is linked to higher rates of coronary heart disease, cardiovascular events, and mortality in both type 1 and type 2 diabetes. This risk is especially high in individuals with significant vascular risk, such as older adults and those with multiple cardiovascular risk factors. Hypoglycemia triggers several pathophysiological changes that increase cardiovascular risk. These include activation of the sympathoadrenal system, promotion of proinflammatory and prothrombotic states, arrhythmogenic changes, and increased hemodynamic stress. Experimental evidence shows that recurrent hypoglycemia worsens microvascular dysfunction and promotes adverse cardiac remodeling, especially in people with diabetes. While the link between hypoglycemia and cardiovascular events is well established, the causality remains debated. Hypoglycemia may directly contribute to cardiovascular disease or indicate underlying vulnerability, especially in patients with advanced disease or comorbidities. Minimizing hypoglycemic episodes is recommended for all patients with diabetes, particularly those with established cardiovascular disease, due to the clear association with adverse outcomes.

## Linked entities

- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), cardiovascular disease (MONDO:0004995), coronary heart disease (MONDO:0005010)

## Full-text entities

- **Genes:** SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}
- **Diseases:** sudden death (MESH:D003645), myocardial infarction (MESH:D009203), microvascular complications (OMIM:603933), CAN (MESH:D002318), Hypoglycemia (MESH:D007003), ventricular ectopy (MESH:D050030), DAN (MESH:D003929), atrial fibrillation (MESH:D001281), insulin resistance (MESH:D007333), microvascular dysfunction (MESH:D017566), thrombosis (MESH:D013927), death in bed syndrome (MESH:D003668), neurological injury (MESH:D020196), altered consciousness (MESH:D003244), brain injury (MESH:D001930), impaired glucose counter-regulation (MESH:C565631), arrhythmic death (MESH:D003643), ASCVD (MESH:D050197), hormonal deficiencies (MESH:D004393), QTc prolongation (MESH:D008133), Autonomic neuropathy (MESH:D009422), cognitive (MESH:D003072), endothelial (MESH:D005642), Type 2 Diabetes (MESH:D003924), neuronal injury (MESH:D009410), renal and retinal problems (MESH:C537580), RESOLVE (MESH:D057768), renal dysfunction (MESH:D007674), depression (MESH:D003866), hypokalemia (MESH:D007008), type 1 diabetes (MESH:D003922), system (MESH:D015619), dysfunction (MESH:D006331), irritability (MESH:D001523), Endothelial dysfunction (MESH:D014652), Diabetes (MESH:D003920), CKD (MESH:D051436), inflammation (MESH:D007249), complications (MESH:D008107), hyperglycemia (MESH:D006943), metabolic disturbances (MESH:D024821), HAAF (MESH:D012791), dyslipidemia (MESH:D050171), coronary heart disease (MESH:D003327), mitochondrial dysfunction (MESH:D028361), ischemia (MESH:D007511), arrhythmic (OMIM:212500), atrial ectopic beats (MESH:D018880), hypoglycemic (MESH:C000721848), bradycardia (MESH:D001919), Autonomic dysfunction (MESH:D001342), dead-in-bed (MESH:D001926), arrhythmia (MESH:D001145), tachycardia (MESH:D013610), Hypo (MESH:D052456), heart block (MESH:D006327), stroke (MESH:D020521), sudden cardiac death (MESH:D016757), confusion (MESH:D003221)
- **Chemicals:** catecholamine (MESH:D002395), antidiabetic medications (-), Glargine (MESH:D000069036), Glimepiride (MESH:C057619), creatinine (MESH:D003404), glucose (MESH:D005947), ROS (MESH:D017382), lipid (MESH:D008055), epinephrine (MESH:D004837), Linagliptin (MESH:D000069476), Diamicron (MESH:D005907), NO (MESH:D009569), blood glucose (MESH:D001786), aspirin (MESH:D001241), sulfonylurea (MESH:D013453)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916416/full.md

## References

82 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916416/full.md

---
Source: https://tomesphere.com/paper/PMC12916416